secwatch.observer — SEC 8-K summary
======================================

Issuer:     IGC Pharma, Inc. (IGC)
CIK:        0001326205
Form:       8-K
Filed at:   2021-12-02T23:59:59+00:00
Accession:  0001185185-21-001785
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IGC Phase 1 trial for THC-based Alzheimer's drug IGC-AD1 shows statistically significant NPI reductions; no SAEs
--------------------------------------------------------------------------------

- Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.
- No serious adverse events or deaths across all cohorts; only one related AE (mild dizziness) reported.
- IGC plans to design a larger multi-site Phase 2/3 trial pending FDA approval for IGC-AD1.
- Sixty-two percent of participants had CYP2C9 intermediate metabolizer phenotype, affecting THC half-life (5.09 h vs 1.73 h for normal).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/0001185185-21-001785-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/indiaglob20211130_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-21-001785

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer